Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease.
We help the cancer community push the field of routine cancer care forward in the following ways:
Patients first. We bring a pan-cancer orientation to the treatment of both solid tumors and hematologic cancers, and help make precision medicine a reality for patients by providing comprehensive genomic profiles to oncologists to help them match their patients to targeted therapies.
Research. We collaborate with drug developers and cancer researchers to identify novel targets and assist in the development of targeted cancer therapies and active clinical trials.
Data. We leverage our molecular information platform, using our growing knowledgebase of genomic information about human cancers and incorporating clinical data, to inform drug development and enable precision medicine.
We are a passionate group of experts in genome technology, cancer biology, clinical oncology and information science. We are also supported by leaders in business development and commercialization.
Working together, we turn our proven science into commercial products that are rapidly becoming a trusted and routine component of cancer care.
Both FoundationOne® and FoundationOne® Heme reveal the alterations that are driving the growth of a patient’s cancer. This information helps physicians to precisely and confidently identify targeted treatment options that may not have been otherwise considered.
FoundationOne and FoundationOne Heme comprehensively and accurately analyze all genes known to be relevant in human cancers, and find all classes of alterations in these genes that may be contributing to a tumor’s growth.
The field is moving rapidly, and new data becomes available almost daily. Our analysis is informed by the latest information available. We provide physicians with concise, yet detailed, user-friendly reports that clearly explain their patients’ genomic alterations and help match them with the available targeted therapies and clinical trials.
Our molecular information platform continues to grow with every test we run, whether for pharmaceutical or for clinical use. This data can be used to continually improve our understanding of cancer and even find new ways to control its growth.
Making an Impact
We’ve made a difference in the lives of thousands of patients already. But, there’s more work to be done.
Our impact so far:
- More than 35,000 patients tested with FoundationOne® or FoundationOne® Heme
- 2 clinical tests on the market
- 315 cancer-related genes assessed by FoundationOne
- 405 cancer-related genes assessed by FoundationOne Heme
- 38 peer-reviewed papers published in 2014
- More than 20 pharma industry partners
We provide two best-in-class genomic tests for patients—FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas. These assays have undergone robust analytic validation and have been proven to be among the most accurate, sensitive, and comprehensive tests available today—which means more options for patient care.
Our test results combine the molecular information from our assays with up-to-date information on the latest scientific and clinical data. We distill this into easy-to-read reports with the most actionable information to help inform patient treatment. We also offer additional materials, services, and real-time data through our technology products, like our Interactive Cancer Explorer®.
We deliver an end-to-end solution from testing to getting access to targeted therapies, enabling you to deliver the best possible care for your patients. Our FoundationACCESS program addresses any financial, access and claim issues for FoundationOne and FoundtaionOne Heme testing. Our Careline program offers comprehensive case management services to help patients who are facing obstacles obtaining prescribed targeted therapies and increase physicians’ ability to act on FoundationOne results, while our Trial Navigator program helps match patients to clinical trials and assists with the enrollment process.
Technology Products & Services
We are creating a dynamic network of users generating valuable information—perhaps the largest database of cancer molecular information in the world, that is easily accessible and can be shared across the cancer community.
Physicians, drug developers, cancer researchers and patient advocates leverage our molecular information platform every day because we connect the dots between real-time patient results, existing therapies and the latest research. Through our products and services, like our Interactive Cancer Explorer, the oncology community has access to genomic and clinical data, advanced analytics and published peer-reviewed research to aid them in treatment decisions and therapy development.
ICE 2 is the latest release of Foundation Medicine’s Interactive Cancer Explorer, which features a brand new approach to increasing the actionability of FoundationOne and FoundationOne Heme results: PatientMatch. With PatientMatch, you can connect with other physicians and share experiences treating patients with similar genomic profiles to inform your treatment decisions.
Pharma Research Collaborations
The molecular information we generate helps drug developers and clinical researchers create newer and better therapies today.
Currently, we collaborate with more than 20 biotech and pharmaceutical companies to help accelerate the development of new targeted therapies.
Our molecular information platform enables these companies to more quickly select the promising drug candidates and to identify genomic signatures and mechanisms of sensitivity or resistance. In turn, this information is used to design more efficient clinical trials to accelerate the delivery of safe, effective targeted therapies for patients with cancer.